Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.04. | TheraVet reports Full-Year 2023 Financial Results and Provides the Preparatory Documents for the General Meeting of June 6th, 2024 | 240 | Business Wire | Significant sales growth in 2023, especially for BIOCERA-VET OSTEOSARCOMA Portfolio strengthened with 4 new products added in 2023, for a total of 15 products Cash position of €1.15... ► Artikel lesen | |
10.04. | TheraVet Reports 2023 Full Year and 2024 First Quarter Revenues | 177 | Business Wire | BIOCERA-VET (whole line) 2023 units sold up 54% Year-on-Year BIOCERA-VET OSTEOSARCOMA up 68% Year-on-Year Six-fold unit sales increase in North America (USA and Canada) in 2023 ... ► Artikel lesen | |
13.03. | TheraVet: BIOCERA-VET is Now Available for the Management of Dental and Orthopedics Conditions in Horses | 141 | Business Wire | Regulatory News:
TheraVet (ISIN: BE0974387194 ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of BIOCERA-VET Equine in countries... ► Artikel lesen | |
20.02. | TheraVet Retains a Leading US Veterinary Consulting Firm to Help Strategize Company Growth on the US Market | 191 | Business Wire | Retaining of a leading consulting firm with a solid track record of upscaling vet companies on the US market To rapidly expand TheraVet presence and be recognized as a major player in the... ► Artikel lesen | |
30.01. | TheraVet SA: TheraVet Strengthens Its Intellectual Property With the Issuance of a Patent on VISCO-VET Technology in Europe, Israël & Singapore | 267 | Business Wire | Regulatory News:
TheraVet (ISIN: BE0974387194 ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces that the European Patent Office (EPO), and the... ► Artikel lesen | |
23.01. | TheraVet reports surge in BIOCERA-VET sales for Q4 2023 | 1 | Investing.com | ||
23.01. | TheraVet Reports an 99% Increase in BIOCERA-VET Units Sold in Q4 2023 | 248 | Business Wire | BIOCERA-VET (whole line) units sold are up 99% Year-on-Year up 27% Quarter-over-Quarter in Q4 2023; they are up 90% Year-on-Year for H2 2023 BIOCERA-VET OSTEOSARCOMA unit sales up 145%... ► Artikel lesen | |
17.01. | TheraVet: Commercial Launch of BIOCERA-VET in Germany | 241 | Business Wire | 13 BIOCERA-VET references now available in Germany, the largest companion animal health market in Europe Attendance to Leipzig Veterinary Congress, the biggest event of the country ... ► Artikel lesen | |
09.01. | TheraVet: Agreement with Alcyon Italia for the Distribution of BIOCERA-VET Product Line in Italy | 271 | Business Wire | 13 BIOCERA-VET references now distributed in Italy Alcyon Italia largest distribution coverage in Italy Multiple clinical trials ongoing with Key Opinion Leaders in Italy
Regulatory... ► Artikel lesen | |
04.01. | TheraVet Reports Significant Success of Its Last Educational Webinar on Canine Osteosarcoma Co-Organized With Veterinary Instrumentation | 264 | Business Wire | 520 registered veterinarians, from United Kingdom and abroad, with 38% of live attendees Cementoplasty with BIOCERA-VET Osteosarcoma highlighted as valuable limb-sparing option Very... ► Artikel lesen | |
06.12.23 | TheraVet Reports Further Achievements on Its Osteosarcoma Program | 237 | Business Wire | Regulatory News:
TheraVet (ISIN: BE0974387194 ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, updates on the Osteosarcoma Program achievements in 2023.
At... ► Artikel lesen | |
23.11.23 | TheraVet: Launch of BIOCERA-VET Canine Osteosarcoma Study Conducted by the Prestigious University of Florida | 350 | Business Wire | Study assessing the efficacy of BIOCERA-VET Osteosarcoma Cementoplasty associated with stereotactic radiotherapy1 Evaluation of the effect on lameness and the risk of pathological fracture... ► Artikel lesen | |
20.11.23 | TheraVet Announces the Setting up of an Equity-Linked Financing Facility and Updates on Its Financing Strategy | 382 | Business Wire | Subscription of an equity-linked financing facility of up to €3 million Financial conditions limited to a discount (5%) on the share price: no fees, commissions, exit penalties or expenses... ► Artikel lesen | |
08.11.23 | TheraVet: Significant Sales Progression for BIOCERA-VET in Q3 2023 | 298 | Business Wire | Over 75% progression of BIOCERA-VETline sales, including 300% increase in BIOCERA-VETOSTEOSARCOMA Symbolic milestone of 1,000 units sold crossed Confirmed success of the recently... ► Artikel lesen | |
25.10.23 | TheraVet Announces the Appointment of a Chief Financial Officer to Reinforce Its Global Financing and Cost Control Strategy | 314 | Business Wire | Regulatory News:
TheraVet (ISIN: BE0974387194 ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announced the appointment of Rodolphe Lebrun as... ► Artikel lesen | |
18.10.23 | TheraVet: Increasingly Successful Attendance in Major Ortho EU & US Conferences and North America Launch of BIOCERA-VET COMBO-CLEAN | 344 | Business Wire | Commercial success at the ESVOT congress and ACVS conference with an ever-growing number of vets visiting TheraVet's booths BIOCERA-VET use for surgical management of canine osteosarcoma... ► Artikel lesen | |
11.10.23 | TheraVet: BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA | 401 | Business Wire | BIOCERA-VET RTU introduced as a breakthrough innovation to treat horse bone cysts at the World Breeding Federation for Sport Horses annual meeting (Orlando, USA) TheraVet' sponsor of the... ► Artikel lesen | |
27.09.23 | TheraVet: Patient Recruitment Phase Successfully Completed in BIOCERA-VET Fracture Revision Surgery Study in Toy Dogs | 301 | Business Wire | Multicentric (4 sites in 3 countries) prospective study assessing BIOCERA-VET in revision surgery of distal radioulnar fracture in toy and miniature dogs A niche market with important unmet... ► Artikel lesen | |
06.09.23 | TheraVet Reports Its 2023 Half-year Results and Provides an Update on the Development of Its Activities | 425 | Business Wire | Sales increased by 29% compared to first half 2022
Number of BIOCERA-VET units distributed1 increased by 31% compared to the first half of 2022, taking into account the successful introduction... ► Artikel lesen | |
11.07.23 | TheraVet provides an update on its 2023 half-year development and portfolio strategy | 404 | Business Wire | Commercial launch of BIOCERA-VET COMBO-CLEAN, a new product reference, in May Strong start for 3 programs in high value markets (Osteosarcoma, Equine and Non-Union) Dense program... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 28,020 | -0,39 % | Enorme Fortschritte - First Majestic Silver, Power Nickel, Bayer Aktie | In den vergangenen Wochen sind die Rohstoffe und Rohstoffaktien im Zuge der Gold- und Silberrally in den Fokus der Anleger gerückt. Viele Aktien aus den beiden Sektoren konnten sich von ihren Tiefstständen... ► Artikel lesen | |
MERCK KGAA | 152,00 | +1,13 % | Dividendenbekanntmachungen (29.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 361 DEGREES INTERNATIONAL LTD KYG884931042 0,139 HKD 0,0166 EUR ACROW LIMITED AU0000006124 0,0285 AUD 0,0174 EUR AGNC INVESTMENT... ► Artikel lesen | |
NOVO NORDISK | 114,02 | -2,21 % | Novo Nordisk vor Zahlen: Das erwarten die Analysten | Europas wertvollstes börsennotiertes Unternehmen öffnet am Donnerstag in dieser Handelswoche (02. Mai) seine Bücher zum ersten Quartal. DER AKTIONÄR zeigt auf, was die Analysten im Durchschnitt vom... ► Artikel lesen | |
CANOPY GROWTH | 9,500 | +0,21 % | Breaking News: Marihuana-Hammer - Tilray, Curaleaf, Canopy & Co explodieren | Das kommt überraschend: In Amerika ändert sich die Einschätzung von Marihuana. Die Drogenbehörde DEA ändert ihre Einstufung von Marihuana auf Schedule III. Damit erkennt sie die medizinische Verwendung... ► Artikel lesen | |
ASTRAZENECA | 140,80 | -0,56 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 13000 Pence auf "Overweight" belassen. Die Resultate für das Mittel Enhertu aus der DB06-Brustkrebs-Studie... ► Artikel lesen | |
ELI LILLY | 684,60 | +0,16 % | Vor den Earnings: Verhageln die Engpässe bei der Abnehmspritze die Earnings für Eli Lilly? | © Foto: Sascha Lotz/dpaDer Erfolg der begehrten Blockbuster Mounjaro und Zepbound könnte Eli Lilly zum Verhängnis werden und für eine negative Überraschung bei den Quartalszahlen sorgen. US-Pharmariese... ► Artikel lesen | |
PFIZER | 25,840 | -0,04 % | Pfizer: Doppelschlag vor den Zahlen - das wird erwartet | Mit Eli Lilly und Merck & Co haben bereits zwei große amerikanische Pharma-Konzerne überzeugende Ergebnisse vorgelegt. Bristol-Myers Squibb hingegen patzte in der vergangenen Handelswoche (DER AKTIONÄR... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 9,550 | +2,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
JAGUAR HEALTH | 0,300 | +1,70 % | Jaguar Health, Inc.: Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease | Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal... ► Artikel lesen | |
SCHOTT PHARMA | 37,960 | +0,69 % | EQS-News: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations | EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Schlagwort(e): Personalie
SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations
30.04.2024 / 17:00 CET/CEST
Für... ► Artikel lesen | |
DERMAPHARM | 33,500 | +4,36 % | Dermapharm: Ein starkes Zeichen - Aktie zieht an | Die Dermapharm-Aktie kann sich am Mitttwoch weiter von ihren Tiefständen lösen und setzt ihren Aufwärtstrend fort. Besonders positiv wirkte sich die heutige Bekanntgabe eines Insiderkaufs aus. Ein bedeutender... ► Artikel lesen | |
TILRAY BRANDS | 1,947 | +0,05 % | Unglaubliche Prognose für Montag setzt Tilray Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
AURORA CANNABIS | 6,270 | +0,24 % | Aurora Cannabis & Canopy Growth stürzen ab - was ist los? | Um mehr als -20% sind am deutschen Feiertag die Aurora Cannabis-Aktie (WKN: A2P4EC) und die Aktie von Canopy Growth (WKN: A140WQA) an der Nasdaq abgestürzt. Was ist los im Cannabis-Sektor? Und wie geht... ► Artikel lesen | |
BRISTOL-MYERS SQUIBB | 40,800 | -0,18 % | Neue Analysteneinschätzung - Carbon Done Right Developments, Bristol Myers Squibb, Deutsche Lufthansa Aktie | Negative Wirtschaftsdaten aus den USA belasteten zuletzt die Indizes. Das abschwächende Wirtschaftswachstum in den USA, wie auch die anhaltende Inflation treiben immer mehr Anlegern die Sorgenfalten... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 3,520 | +7,32 % | Aquestive stock falls amid Libervant approval, Anaphylm update |